Advertisement
Advertisement

EBS

EBS logo

Emergent Biosolutions, Inc.

5.71
USD
+0.23
+4.08%
Mar 14, 15:58 UTC -4
Closed
exchange

After-Market

5.855

+0.15
+2.54%

Emergent Biosolutions, Inc. Profile

About

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.

Info & Links

CEO

Joseph C. Papa

Headquarters

300 Professional Drive
GAITHERSBURG, MD 20879, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.emergentbiosolutions.com

Auditor

Ernst & Young LLP

Share holders

19

Employees

1,600

Emergent Biosolutions, Inc. Statistics

Valuation Measures

Market Capitalization2

317.25M

Enterprise Value

823.45M

Enterprise Value/EBITDA(ttm)

-41.80

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

0.38

Price to Book(mrq)

0.84

Price to Cash(ytd)

8.92

Profitability

Gross Margin(ttm)

31.74%

Operating Margin(ttm)

-4.86%

Profit Margin(ttm)

-21.74%

Return on Equity(ttm)

-9.91%

Return on Invested Capital(ttm)

-27.87%

Return on Assets(ttm)

-3.31%

Income Statement

Revenue(ttm)

1.13B

Revenue Per Share(ttm)

20.77

Gross Profit(ttm)

377.10M

EBITDA(ttm)3

-19.70M

Net Income Available to Common(ttm)

-208.80M

Diluted EPS(ttm)

-4.10

Share Statistics

Beta (5Y Monthly)

1.62

52-Week Change

154.91%

S&P 500 52-Week Change

9.48%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

54.18M

Dividend Yield

0.00%

Float4

53.53M

% Held by Insiders

1.20%

% Held by Institutions

78.40%

Balance Sheet

Total Cash(mrq)

156.40M

Total Cash Per Share(mrq)

2.89

Total Debt(mrq)

662.60M

Total Debt/Equity(mrq)

130.33%

Current Ratio(mrq)

2.88%

Quick Ratio(mrq)

1.47%

Book Value Per Share(mrq)

9.40

Cash Flow

Operating Cash Flow Per Share(ytd)

2.49

Free Cash Flow(ytd)

125.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement